FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-02								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					- 01	360	1011 30(11)	or the	iiivestiile	TIL CO	прапу Аст	01 1940								
Name and Address of Reporting Person*     Peraza Lisa					H	2. Issuer Name <b>and</b> Ticker or Trading Symbol HERON THERAPEUTICS, INC. /DE/ HRTX								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (cive title						
(Last) 4242 CA	,	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 10/13/2021								X Officer (give title below) Other (specify below)  VP, Chief Accounting Officer						
SUITE 200						If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable						
(Street) SAN DI	Street) SAN DIEGO CA 92121													Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting						
(City)	(S	itate)	(Zip)												Person					
		Tal	ole I - No	n-Deriv	vative	e Se	ecuritie	s Ac	quired	, Dis	posed o	f, or Be	neficia	ally (	Owned					
1. Title of Security (Instr. 3)  2. Transal Date (Month/Date)					Execution Date,		Transaction Dis		4. Securiti Disposed	4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			and 5) Securities Beneficially Owned Following Reported Transcotton(c)		(l) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
										v	Amount (A) or (D) Pri						Price		(Instr. 4)	
Common Stock				10/13	10/13/2021				M		552	A	(1		14,388		D			
Common	n Stock		10/13	3/2021				F		191	D <sup>(2)</sup>	\$10	.55	14,197			D			
			Table II -								osed of, convertil				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	ed A	4. Transaction Code (Instr. 8)		5. Number of		6. Date Exercis Expiration Date (Month/Day/Ye		sable and e	7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)		nt 8.	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amour or Number of Shares	er						
Restricted Stock Units	(1)	10/13/2021			М			552	(3)		(3)	Common Stock	552		\$0.00	6,625		D		
Employee Stock Option (Right to Buy)	\$10.55	10/13/2021			A		13,013		(4)		10/13/2031	Common Stock	13,01	3	\$0.00	13,013	3	D		
Restricted Stock	\$0.00	10/13/2021			A		23,424		(5)		(5)	Common	23.42	4	\$0.00	23,424	4	D		

## Explanation of Responses:

- 1. Restricted stock units convert into common stock on a one-for-one basis.
- 2. Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
- $3. \ The \ restricted \ stock \ units \ vest \ in \ 16 \ equal \ quarterly \ installments \ beginning \ one \ quarter \ after \ the \ date \ of \ grant \ (10/13/2020).$
- 4. The stock option vests and becomes exercisable monthly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that the stock option will be fully vested on the four year anniversary of the date of grant.
- 5. The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant.

## Remarks:

/s/ Lisa Peraza

10/15/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.